On November 3, 2016 Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, reported that seven oral and four poster presentations detailing updated clinical and preclinical results generated in partnership with its collaborators will be presented at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Juno, NOV 3, 2016, View Source;p=RssLanding&cat=news&id=2219226 [SID1234516282]). Senior executives will also review results and provide an update on Juno’s clinical development program at an analyst and investor event, which will also be available via webcast.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Presentations at ASH (Free ASH Whitepaper) will showcase new data that support our best-in-class CAR T strategy across a range of B-cell malignancies," said Mark J. Gilbert, M.D., Juno’s Chief Medical Officer. "The responses we are seeing with our product candidates, including updated JCAR017 results in adults with relapsed/refractory NHL, demonstrate the potential of our CAR T programs for patients in need of more treatment options. We are also learning more about cell characterization and toxicities, which are critical to improving the patient experience, our product candidates’ benefit-to-risk ratio, and potentially moving CAR T treatment into earlier lines of therapy."
New data with JCAR017 in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which is a subtype of NHL, and final data from the PLAT-02 trial for pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL) will be presented. JCAR017 uses a defined CD4:CD8 cell composition and 4-1BB as the costimulatory domain, which differentiates it from other CD19-directed CAR T product candidates advancing to commercialization. In addition, final data from a Phase I trial with JCAR014 in high-risk, ibrutinib-refractory patients with chronic lymphocytic leukemia (CLL) will also be presented in an oral presentation.
The following will be presented at ASH (Free ASH Whitepaper):
Oral Presentations
CD19 CAR T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia (Abstract #56)
Presenter: Cameron J. Turtle, M.B.B.S., Ph.D., Fred Hutchinson Cancer Research Center
Date: Saturday, December 3, 2016, 7:45 a.m. Pacific Time
Location: San Diego Convention Center, Room 6AB
Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL (Abstract #58)
Presenter: Mark B. Geyer, M.D., Memorial Sloan Kettering Cancer Center
Date: Saturday, December 3, 2016, 8:15 a.m. Pacific Time
Location: San Diego Convention Center, Room 6AB
CD19 CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL (Abstract #219)
Presenter: Rebecca Gardner, M.D., Seattle Children’s Research Institute
Date: Saturday, December 3, 2016, 4:30 p.m. Pacific Time
Location: Marriott Marquis San Diego Marina, Marriott Grand Ballroom Salons 11-13
Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (Abstract #650)
Presenter: Nirali Shah, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute
Date: Monday, December 5, 2016, 7:15 a.m. Pacific Time
Location: San Diego Convention Center, Room 6CF
Creation of The First Non-Human Primate (NHP) Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T cell-mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-directed CAR T Cell Therapy (Abstract #651)
Presenter: Agne Taraseviciute, Seattle Children’s Research Institute
Date: Monday, December 5, 2016, 7:15 a.m. Pacific Time
Location: San Diego Convention Center, Room 6CF
Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR T Cell Toxicity Management (Abstract #586)
Presenter: Rebecca Gardner, M.D., Seattle Children’s Research Institute
Date: Monday, December 5, 2016, 7:45 a.m. Pacific Time
Location: Marriott Marquis San Diego Marina, Marriott Grand Ballroom Salons 2-4
EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML (Abstract #1001)
Presenter: Aude G. Chapuis, M.D., Fred Hutchinson Cancer Research Center
Date: Monday, December 5, 2016, 3:45 p.m. Pacific Time
Location: San Diego Convention Center, Room 24
Poster Presentations
Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity by Cell Dose (Abstract #1852)
Presenter: Cameron J. Turtle, M.B.B.S., Ph.D., Fred Hutchinson Cancer Research Center
Date: Saturday, December 3, 2016, 5:30 p.m. – 7:30 p.m. Pacific Time
Location: San Diego Convention Center, Hall GH
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia (Abstract #3231)
Presenter: Jim Qin, Senior Research Associate, Juno Therapeutics
Date: Sunday, December 4, 2016, 6:00 p.m. – 8:00 p.m. Pacific Time
Location: San Diego Convention Center, Hall GH
Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Abstract #4192)
Presenter: Jeremy S. Abramson, Massachusetts General Hospital Cancer Center
Date: Monday, December 5, 2016, 6:00 p.m. – 8:00 p.m. Pacific Time
Location: San Diego Convention Center, Hall GH
Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells (Abstract #4712)
Presenter: Jonathan Rosen, Ph.D., Senior Director, Research & Technology Core, Fate Therapeutics
Date: Monday, December 5, 2016, 6:00 p.m. – 8:00 p.m. Pacific Time
Location: San Diego Convention Center, Hall GH